Staging for liver cancer.
This article focuses on the development of prognostic scores, their use in the management of cancer patients, and how they are different from staging systems. It is underlined that the development of a prognostic score is a dynamic process. The score can be modified by incorporating new prognostic features provided that appropriate methodology is followed. The peculiarity of hepatocellular carcinoma patients are addressed, and each individual prognostic systems for hepatocellular carcinoma is presented and discussed.
Daniele
Bruno
B
Medical Oncology Unit, G. Rummo Hospital, Benevento, Italy. bruno.daniele@ao-rummo.it
Perrone
Francesco
F
D014408:Biomarkers, Tumor / Q000097:blood; D001707:Biopsy, Needle; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D003952:Diagnostic Imaging / Q000379:methods; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007391:International Cooperation; D008113:Liver Neoplasms / Q000453:epidemiology / Q000473:pathology*; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging / Q000379:methods*; D011379:Prognosis; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor